🏢 官网IRLUNGCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:05:34·⟳ 抓取 04:10:33 +4m59s·⚡ 决策 07-29 04:11:22 +49s·91.1 天前
Pulmonx宣布参加Canaccord Genuity年度成长会议炉边谈话
这只是公司参加投资者会议并提供网络直播的日程公告，没有披露订单、审批、临床、业绩或指引等新增经营信息。
📄 原文LUNG↗ 原文
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader…
不做 Pulmonx（LUNG.US）
例行投资者会议参会公告，无明确方向、无可量化经营增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 这只是公司参加投资者会议并提供网络直播的日程公告，没有披露订单、审批、临床、业绩或指引等新增经营信息。
主要风险
- 无可交易的同向催化；会议本身可能带来后续信息，但当前公告不改变基本面预期。
原文全文
展开原文 · 1,672 字
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46
th
Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX
®
Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr
®
Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx
®
, AeriSeal
®
, Chartis
®
, LungTraX
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
th
Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX
®
Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr
®
Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx
®
, AeriSeal
®
, Chartis
®
, LungTraX
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。